Evaluation of Factors Influencing Outcomes in Pauci-Immune Crescentic Glomerulonephritis: Single Centre Experience of 51 Cases

Introduction: Pauci-immune crescentic glomerulonephritis (PICGN) is rare form of glomerulonephritis that frequently presents as rapidly progressive renal failure. Several prior studies have evaluated role of various factors influencing outcomes in patients with PICGN. The histopathological classification proposed by Berden a decade earlier described difference in the outcomes of patients in the focal, crescentic, mixed and sclerotic category with best prognosis for focal and worst for sclerotic group. The newly proposed renal risk score of Brix takes into account both the histopathological parameters (% of normal glomeruli, tubular atrophy and interstitial fibrosis) and clinical parameter (eGFR) which influences outcome. Methods: Retrospective study was performed between 2014 to 2018. Biochemical parameters and ANCA details were recorded and renal histopathology slides were reviewed and classified according to Berden's histopathologic classes. All the cases were further characterized into three groups based on renal risk score (Brix et al). Univariate, multivariate analysis for risk factors predicting ESRD and Kaplan Meier Survival Analysis were done. Results: In the present study, we found eGFR (P 0.024), % of normal glomeruli (P 0.023) and IFTA (P 0.001) as important factors influencing renal outcome in patients with PICGN. More than 60% patients achieved complete remission with low renal risk score as compared to patients with high renal risk score in which 80% patients developed ESRD or death at follow up. We also found significant difference in survival among various renal risk categories (Log-Rank P = 0.001) as compared to Berden's international histological classification (Log-Rank P = 0.037) on Kaplan –Meier survival analysis. Conclusion: PICGN is a significant cause of mortality and morbidity. Renal histological factors such as % normal glomeruli at time of biopsy, degree of IFTA and renal risk score play an important role in assessing prognosis in these patients.

[1]  U. Panzer,et al.  Development and validation of a renal risk score in ANCA-associated glomerulonephritis. , 2018, Kidney international.

[2]  J. Boletis,et al.  The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries , 2015, Kidney Diseases.

[3]  J. Levy,et al.  Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  S. Stancu,et al.  ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study , 2015, BMC Nephrology.

[5]  S. Quaglini,et al.  Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature. , 2015, Clinical and experimental rheumatology.

[6]  V. Jha,et al.  Histopathological classification of pauci-immune glomerulonephritis and its impact on outcome , 2014, Rheumatology International.

[7]  L. Racusen,et al.  Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome , 2013, BMC Nephrology.

[8]  Y. Asada,et al.  Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis , 2013, BMC Nephrology.

[9]  Min Chen,et al.  Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  R. Waldherr,et al.  Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. , 2012, Journal of the American Society of Nephrology : JASN.

[11]  B. Stephany Primary Glomerular Diseases , 2010 .

[12]  Su-xia Wang,et al.  Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis. , 2007, Journal of the American Society of Nephrology : JASN.

[13]  C. Pusey,et al.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  C. Franssen,et al.  Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. , 2003, Kidney international.

[15]  R. Falk,et al.  ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. , 2000, Seminars in nephrology.

[16]  R. Falk,et al.  Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.

[17]  Penny Ackland,et al.  Kidney disease , 2019, Analgesia, Anaesthesia and Pregnancy.